Occam Places Radu Dobrin as CTO of Deep Genomics

Occam Places Radu Dobrin as CTO of Deep Genomics

In June 2024, Occam placed Radu Dobrin as the Chief Technology Officer of Deep Genomicsa Toronto-based artificial intelligence drug development venture. Dobrin brings diverse and extensive experience in various scientific and biopharmaceutical organizations at the intersection of computation and wet science.   


He began his impressive career in drug research at Rosetta Inpharmatics, Merck, Janssen, and BMS where he held the title Executive Director and Head of Bioinformatics Immunology & Oncology in TRCs and Early Development. He then shifted into biotechnology at Pathos, a clinical-stage biotech leveraging AI for drug development, where he served as SVP Translational Sciences. 


Radu holds a BS and MS in Physics from Babes-Bolyai University and a MS in Computer Engineering and PhD in Physics from Michigan State University.


About Deep Genomics


Founded in 2015 by Brendan Frey and funded by investors including SoftBank, and Khosla Ventures, Deep Genomics applies AI and machine-learning techniques to query RNA biology, discovering targets for its medicines and designing therapies that can address those targets. The Board is a formidable amalgamation of both tech and biotech luminaries, including Yann LeCun, Chief AI Officer of Meta.


Occam Global’s Focus on Executive Recruiting for Artificial Intelligence


Occam's vast experience recruiting artificial intelligence and machine learning talent for life sciences organizations provides them with the network and skills to solve the most challenging searches.  Several of Occam's clients incorporate AI/ML at one or multiple stages of R&D, and Occam has completed several searches across roles such as Chief Data Officer, Chief Technology Officer, and Chief Platform Officer.  Contact Occam Global for your biotech executive recruiting needs today.   

About Occam Global

Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.